Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

PHASE3TerminatedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

October 7, 2020

Study Completion Date

October 28, 2020

Conditions
Surgical Site Infection
Interventions
DRUG

Delafloxacin

Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days

DRUG

Vancomycin

Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days

DRUG

Linezolid

Solution for infusion or tablet, 600 mg BID, for 5 to 14 days

DRUG

Piperacillin/Tazobactam

Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days

DRUG

Tigecycline

Powder for solution for infusion 50 mg, TID, for 5 to 14 days

Trial Locations (1)

Unknown

Hospital Agostino Gemelli, Roma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT04042077 - Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections | Biotech Hunter | Biotech Hunter